Theravance Bioph Stock Price, News & Analysis

Theravance Biopharma (NASDAQ:TBPH) reported strong Q2 2025 financial results, highlighted by YUPELRI® net sales of $66.3 million, representing a 22% year-over-year increase. The company completed a significant transaction, selling its TRELEGY ELLIPTA royalty interest to GSK for $225 million.

Key financial metrics include total revenue of $26.2 million and a net income of $54.8 million. The company maintains a robust balance sheet with $338.8 million in cash and no debt. The pivotal Phase 3 CYPRESS study for ampreloxetine is expected to complete enrollment by late summer, with top-line data anticipated six months later.

TRELEGY's year-to-date performance puts it on track to trigger a $50 million milestone payment in 2025, with Q2 2025 global net sales reaching approximately $1.1 billion.

Theravance Biopharma (NASDAQ: TBPH) has scheduled its second quarter 2025 financial results announcement and business update for August 12, 2025, after market close. The company will host a conference call and webcast at 5:00 pm ET on the same day.

Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through the company's website. A replay will be available for 30 days through September 11, 2025.

Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company will engage in a fireside chat on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Senior management will also be available for one-on-one meetings with investors during the conference.

Interested parties can access the webcast or schedule meetings through their BTIG representative or by emailing uscorporateaccess@btig.com.

Theravance Biopharma (NASDAQ:TBPH) announced that its partner Viatris has received approval from China's NMPA for YUPELRI® (revefenacin), the first once-daily nebulized LAMA for COPD maintenance treatment in China.

The approval triggers a $7.5 million milestone payment to TBPH, with potential for additional sales-based milestones up to $37.5 million and tiered royalties of 14% to 20% on net sales in China. Viatris will handle all commercialization aspects.

TBPH's financial position includes $131 million in cash, $225 million from TRELEGY royalties sale to GSK, 35% of U.S. YUPELRI profits, and up to $150 million in potential TRELEGY milestone payments.

Theravance Biopharma (TBPH) has agreed to sell its remaining royalty interest in Trelegy Ellipta to GSK for $225 million in cash. This deal follows the company's 2022 transaction with Royalty Pharma that generated $1.1 billion upfront. TBPH retains rights to potential milestone payments of up to $150 million from Royalty Pharma based on Trelegy's sales performance in 2025 ($50M for ~$3.41B in sales) and 2026 ($100M for ~$3.51B in sales). The transaction represents the first outcome from the Strategic Review Committee's efforts to maximize shareholder value, with the Board remaining committed to returning excess capital to shareholders. The total potential lifetime value from Trelegy Ellipta monetization efforts could reach $1.525 billion, including previous transactions.

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City. The company will engage in a Fireside Chat on Tuesday, May 20 at 10:30 AM EDT at NASDAQ. Additionally, TBPH will conduct in-person meetings with the investment community during the conference.

Investors can access the webcast through Theravance's website under the Investors section, Events and Presentations. The webcast recording will remain available for replay on the company's website for 30 days following the event.

Theravance Biopharma (NASDAQ: TBPH) presented analyses of its Phase 3 program for ampreloxetine, a treatment for symptomatic neurogenic orthostatic hypotension (nOH), at the International MSA Congress. The subgroup analysis from the REDWOOD 0170 study showed that Multiple System Atrophy (MSA) patients experienced meaningful improvement in nOH symptoms after 16 weeks of treatment, with symptoms remaining stable in the ampreloxetine group while worsening in the placebo group.

Key findings revealed improved functional activities in treated patients and demonstrated ampreloxetine's sustained effect on standing blood pressure. Additional analysis from Study 0169 highlighted that MSA patients had the highest nOH symptom burden despite existing treatments, emphasizing the need for better therapies. These results support the ongoing CYPRESS registrational study in nOH and MSA patients.

Theravance Biopharma (TBPH) reported its Q1 2025 financial results, highlighting strong performance across key products. YUPELRI achieved US net sales of $58.3 million, up 6% year-over-year, with notable 48% growth in hospital channel doses. TRELEGY posted global net sales of $854 million, representing a 14% increase from Q1 2024.

The company reported total revenue of $15.4 million and a net loss of $13.6 million. Quarter-end cash balance stood at $130.9 million with no debt. R&D expenses were $11.5 million, while SG&A expenses reached $18.4 million.

The CYPRESS study for ampreloxetine, targeting neurogenic orthostatic hypotension in MSA patients, is nearing completion with final patient enrollment expected by late summer. The company's Strategic Review Committee continues to evaluate alternatives to enhance shareholder value.

Theravance Biopharma (NASDAQ: TBPH) has announced upcoming presentations of analyses from their ampreloxetine Phase 3 program at the International MSA Congress in Boston, May 9-11, 2025. The analyses focus on Studies 169 and 170, supporting ampreloxetine's potential in treating neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) patients.

The presentations include a plenary oral session and poster sessions featuring:

• A pre-specified subgroup analysis of a phase 3 trial by Norcliffe-Kaufmann L, et al.
• Analysis of symptomatic nOH impact on symptom burden by Iodice V, et al.

These analyses support the ongoing CYPRESS registrational study (NCT05696717) in patients with nOH and MSA, demonstrating the company's commitment to understanding ampreloxetine's selective mechanism of action.